Early Cerebral Blood Volume Changes Predict Progression After Convection-Enhanced Delivery of Topotecan for Recurrent Malignant Glioma.

摘要: Objective To assess whether early changes in enhancing tumor volume (eTV) and relative cerebral blood (rCBV) 1 month after convection-enhanced delivery of topotecan patients with recurrent malignant glioma correlated 6-month disease progression status. Methods Sixteen were enrolled a Phase Ib trial for glioma. Each patient was evaluated serial follow-up magnetic resonance imaging at baseline 4- to 8-week intervals. Changes compared eTV rCBV as potential predictors status, classified either progressive or nonprogressive disease. Relationships between percent the probability 6 months estimated by use logistic regression analysis. Receiver operating characteristic curves varying change thresholds reference. Results There significant difference those (+12% vs. −29%, P = 0.02). Logistic analysis demonstrated on average that 10% increase associated 1.7 times odds developing 6 months (95% confidence interval [CI] 1.0–2.9 0.05). determining showed greater area under curve (0.867; 95% CI 0.66–1.00) than (0.767; 0.51–1.00). Conclusion In this selected population treated topotecan, 4 weeks therapy may help predict status months.